Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 152, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103014
Keywords
CD47; TSP-1; innate checkpoint; immunotherapy; cancer therapy
Categories
Funding
- National Natural Science Foundation of China [81772693, 81372446, 81603478]
- Key research and development program of science technology department of Sichuan province [2019YFS0317]
Ask authors/readers for more resources
Cancer immunotherapy using checkpoint blockade has brought about a paradigm shift in the treatment of advanced-stage cancers. Unfortunately, not all patients benefit from these therapies, paving the way for other immune checkpoints to be targeted. CD47, a 'marker-of-self protein that is overexpressed broadly across tumor types, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy. Recently, CD47 blockade by Hu5F9-G4 has shown promise combined with Rituximab in non-Hodgkin's lymphoma. Here we review the complex structure and various physiological functions of CD47 and their implications in cancer biology. Further, this review considers future directions and challenges in advancing this promising target platform to widespread therapeutic use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available